Search research articles
Contact Us
Filters
Showing results (211-220 of 425) with videos related to
Page
of 43
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 11, 2016
Productivity losses associated with cardiovascular disease: a systematic review
Adam L Gordois, Peter P Toth, Ruben Gw Quek, et al.
Current Pharmaceutical Design
|
October 11, 2016
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
Dragana Nikolic, Giuseppa Castellino, Maciej Banach, et al.
Journal of the American Heart Association
|
September 2, 2017
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
Harold E Bays, Lawrence A Leiter, Helen M Colhoun, et al.
European Heart Journal
|
December 25, 2019
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
William E Boden, Deepak L Bhatt, Peter P Toth, et al.
Journal of the American Heart Association
|
March 3, 2020
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
Peter P Toth, Steven R Jones, Maria Laura Monsalvo, et al.
Journal of the American Heart Association
|
September 8, 2022
Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol
Peter P Toth, Sarah Bray, Guillermo Villa, et al.
Journal of Clinical Lipidology
|
December 7, 2016
The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin
Osman Baspınar, Fahri Bayram, Selda Korkmaz, et al.
Angiology
|
May 3, 2013
New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis
Mariusz Stepien, Anna Stepien, Maciej Banach, et al.
Current Atherosclerosis Reports
|
March 12, 2018
Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation
Angelos D Karagiannis, Martin Liu, Peter P Toth, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
October 16, 2020
Beyond cardiovascular medicine: potential future uses of icosapent ethyl
Deepak L Bhatt, Mark A Hull, Mingyang Song, et al.
Page
of 43
Search research articles
Search
Showing results (211-220 of 425) with videos related to
Sort By:
Page
of 43
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 11, 2016
Productivity losses associated with cardiovascular disease: a systematic review
Adam L Gordois, Peter P Toth, Ruben Gw Quek, et al.
Current Pharmaceutical Design
|
October 11, 2016
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
Dragana Nikolic, Giuseppa Castellino, Maciej Banach, et al.
Journal of the American Heart Association
|
September 2, 2017
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
Harold E Bays, Lawrence A Leiter, Helen M Colhoun, et al.
European Heart Journal
|
December 25, 2019
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
William E Boden, Deepak L Bhatt, Peter P Toth, et al.
Journal of the American Heart Association
|
March 3, 2020
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
Peter P Toth, Steven R Jones, Maria Laura Monsalvo, et al.
Journal of the American Heart Association
|
September 8, 2022
Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol
Peter P Toth, Sarah Bray, Guillermo Villa, et al.
Journal of Clinical Lipidology
|
December 7, 2016
The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin
Osman Baspınar, Fahri Bayram, Selda Korkmaz, et al.
Angiology
|
May 3, 2013
New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis
Mariusz Stepien, Anna Stepien, Maciej Banach, et al.
Current Atherosclerosis Reports
|
March 12, 2018
Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation
Angelos D Karagiannis, Martin Liu, Peter P Toth, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
October 16, 2020
Beyond cardiovascular medicine: potential future uses of icosapent ethyl
Deepak L Bhatt, Mark A Hull, Mingyang Song, et al.
Page
of 43